Product Liability Litigation: 'Stand And Fight' Strategy Pays Off For Drug And Device Makers
Executive Summary
Legal analytics company Lex Machina finds that manufacturers most often win at summary judgement stage; however, about 96% of cases settle or are resolved procedurally.
You may also be interested in...
Product Liability Litigation Playbook: Pros And Cons For Pharma
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
‘Skinny Label’ Case Gives Brands A ‘Blueprint’ To Alter Use Codes In Patent Litigation
Federal Circuit ruling in GSK v. Teva shows brands can broaden a use code to include other patented indications years into litigation, AAM attorney says. The case is ‘scarier’ for biosimilar makers since they must market their products, Teva lawyer notes.
US FDA’s PANDA Policy Could Pose Legal Problems For Biosimilars, Attorney Says
Agency’s apparent ‘intellectual exercise’ in treating pre-Hatch-Waxman ANDAs as NDAs could expose biosimilars to liability, Teva deputy general counsel notes at FDLI conference.